ClinicalTrials.gg
CompletedNCT02727205Updated Apr 4, 2016

Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch

A Phase 1 interventional study of Rotigotine Transdermal System in Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch, sponsored by Inflamax Research Incorporated. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-04.

Sponsored by Inflamax Research Incorporated · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
260
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

STUDY TITLE:

A Multiple Site Study to Evaluate the Irritation and Sensitization Potential of Repeat Applications of Rotigotine Transdermal System, 1 mg/24 hr Versus Neupro (Rotigotine Transdermal System), 1 mg/24 hr in Healthy Volunteers

TEST DRUG / INVESTIGATIONAL PRODUCT:

Rotigotine Transdermal System, 1 mg/24 hr

INDICATION STUDIED:

Bioequivalence - Irritation and Sensitization

STUDY DESIGN:

  • Multiple-site, randomized, multiple-application, evaluator-blinded, controlled study
  • One-half (½) of the test patch and one-half (½) of the reference patch was applied daily to the same site for each product over a 21 day period followed by a rest phase and a challenge phase
02

Conditions studied

  • Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch
03

In context

Lead sponsor

Inflamax Research Incorporated is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and non-pregnant female volunteers. All subjects were healthy, non-smoking male and female (nonpregnant) volunteers between the ages of 18 and 65, who were demonstrated to be generally healthy by screening medical and medication history, physical examinations, vital signs, 12-lead (ECG), and FSH levels (if applicable).

Exclusion criteria

Exclusion Criteria:

  1. Reported receiving any drug within 30 days prior to Day 1 patch application.
  2. Reported a illness during the 28 days prior to Day 1 patch application (as determined by the Investigator[s]).
  3. Reported a history of allergic response(s) to rotigotine or related drugs.
  4. Reported a history of sulfite sensitivity.
  5. Demonstrated a clinically relevant finding, as determined by the clinical Investigator(s), on the screening , such as a second- or third-degree atrioventricular block or complete bundle branch block, or arrhythmias.
  6. Reported a history of asthma, orthostatic hypotension, dizziness, syncope, or dyskinesia. At the discretion of the Principal Investigator, subjects with a history of asthma or mild asthma not requiring regular treatment could have been included.
  7. Systolic blood pressure \< 100 or >145 mmHg or diastolic blood pressure \< 60 or > 95 mmHg at screening measured in supine position after 5 minutes rest; heart rate \< 50 or > 100 at screening.
  8. Reported a history of narrow angle glaucoma.
  9. Reported the use of monoamine oxidase (MAO) inhibitors, reserpine, methyldopa, antipsychotics, neuroleptics, benzodiazepines, antidepressants, clozapine, olanzapine, quetiapine, metoclopramide, or risperidone within 3 months of enrollment.
  10. Reported a history of somnolence and/or of falling asleep without warning.
  11. Reported a history of significant dermatologic diseases or conditions such as atopy, or psoriasis.
  12. Reported a history of medical conditions known to alter skin appearance or physiologic response (eg diabetes, porphyria).
  13. Reported a history of significant dermatologic cancers (eg melanoma, squamous cell carcinoma). Basal cell carcinomas that were superficial and did not involve the investigative sites were acceptable.
  14. Reported a history of conditions that would significantly influence the immune response (e.g. primary or acquired immunodeficiencies such as positive or AIDS, or generalized drug reaction, neoplasms such as lymphoma or leukemia, moderate or severe rheumatoid arthritis or active systemic lupus erythematosus).
  15. Demonstrated an obvious difference in skin color amongst application sites, presence of a skin condition, excessive hair (subjects that agreed to have their hair clipped short [not shaved] prior to patch application were eligible), scar tissue, recent sunburn, tattoo, open sore, body piercing, or branding at the intended sites of application that would interfere with placement of study articles, skin assessment or reactions to drug.
  16. Reported the use of any drugs, including systemic and topical and retinoids within 28 days prior to Day 1 patch application.
  17. Reported the use of any medications or treatments that would significantly influence or exaggerate responses to the patches or that would alter inflammatory or immune responses to the patches within 21 days prior to Day 1 patch application (e.g. cyclosporine, tacrolimus, systemic or topical corticosteroids, cytotoxic drugs, immune globulin, Bacillus Calmette-Guerin [BCG], monoclonal antibodies, radiation therapy).
  18. Reported the use of any anti-inflammatory medication, including ibuprofen and Celebrex, within 72 hours of Day 1 patch application, with the exception of steroid nose drops and/or eye drops.
  19. Reported the use of antihistamines or topical drugs at the patch site within 72 hours of Day 1 patch application.
  20. Reported a history of anaphylactic reaction to drugs. At the discretion of the Investigator, subjects with seasonal allergic rhinitis with sensitivity to environmental allergens could have been included.
  21. Reported a history of sensitivity or allergy to adhesive bandages, tapes, or transdermal systems.
  22. Reported a significant history of allergy to soaps, lotions, emollients, ointments, creams, cosmetics, adhesives, or latex.
  23. Reported a history of drug or alcohol addiction or abuse within the past year.
  24. Was pregnant, lactating, breastfeeding, or intended to become pregnant over the course of the study (females only).
  25. Demonstrated a positive pregnancy screen (females only). Subjects with a positive result at screening were to be excluded from the study. Subjects with a positive result during the study were to be withdrawn.
  26. Reported smoking or using tobacco products or was currently using nicotine products (patches, gums, etc.). Ninety (90) days abstinence was required.
  27. Reported a plan to undergo magnetic resonance imaging or cardioversion procedures during the study period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    Single Arm

    One-half (½) of the test patch and one-half (½) of the reference patch (Rotigotine Transdermal System) was applied daily to the same site for each product over a 21 day period followed by a 14 day rest phase and a 48 hour challenge phase.

    Drug: Rotigotine Transdermal System

Interventions

06

What researchers measure

Primary outcomes

  1. Irritation

    The primary endpoint of cumulative irritation was the measurement of the combined "Dermal response" and "Other Effect" total irritation scores recorded during the 21 day continuous application period (i.e. the total irritation score for a specific subject was the sum of the irritation scores recorded on Days 2 through 22 for each patch type). Because the cumulative irritation scores did not display a normal distribution, the primary analysis was a comparison of the overall median of the observed total irritation score of the Test patch against the Reference patch. The Per Protocol Population for Irritation (PPPI) was used for the primary analysis

    Time frame: 21 days (Induction Phase)

  2. Sensitization

    The primary analysis of sensitization used the Per Protocol Population for Sensitization (PPPS) and compared the number and percentage (%) of reactions indicating potential sensitization (irritation score greater than or equal to 2 at 48 or 72 hours post-removal, along with the Investigator's assessment) observed with each patch type

    Time frame: 48 and 72 hour post removal of patch after the challenge phase.

Secondary outcomes

  1. Adhesion

    Adhesion scores

    Time frame: 21 days (Induction Phase) and 1 day Sensitization Phase

07

Study locations

2 sites
  • Clinical Pharmacology of Miami, Inc.
    Miami, Florida 33014, United States
  • Inflamax Research Inc.
    Mississauga, Ontario L4W 1A4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2016
First posted
Apr 4, 2016
Start
Aug 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Last update
Apr 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02727205
Lead sponsor
Inflamax Research Incorporated
Responsible party
Piyush Patel, MD (Medical Director, Inflamax Research Incorporated) — Principal investigator
First posted
Apr 4, 2016
Start date
Aug 2013
Primary completion
Oct 2013
Completion
Oct 2013
Last update
Apr 4, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion